News Sentiment

MLYS sentiment intelligence

Mineralys Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 27.09 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 60

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.5% over one week, +10.0% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction -4.5% Price reacting lower
Trend fit Trend inactive 10.0% over four weeks
Fair value 49.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 46
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 60
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
Market source 10
Investing.com 4
Motley Fool 3
TradingView 3
Insider Monkey 3
Investing.com South Africa 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 49
Earnings 15
Deals and strategy 2
Regulatory and legal 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 68
Moomoo Direct company coverage

Have Mineralys Therapeutics Insiders Been Selling Stock?

This article analyzes recent insider selling activity at Mineralys Therapeutics. It investigates whether insiders have been selling stock and what the implications might be for investors. The article aims to inform readers about the extent and trends of these insider transactions

Tone
Negative 30/100
Event
Market update
Published
03 Jul 2026 18:12
Source
Moomoo
Simply Wall Street Direct company coverage

Have Insiders Sold Mineralys Therapeutics Shares Recently?

Mineralys Therapeutics President Jon Congleton recently sold US$2.0m worth of shares, decreasing his holding by 14%. This sale, along with a larger one earlier in the year, indicates a trend of insider selling. Despite existing insider ownership, the lack of recent insider buying

Tone
Negative 38/100
Event
Market update
Published
03 Jul 2026 12:12
Source
Simply Wall Street